Efficacy of pertussis components in an acellular vaccine, as assessed in a murine model of respiratory infection and a murine intracerebral challenge model

Vaccine

Volumn 20, Issue 9-10, 2002, Pages 1429-1434

  Watanabe, Mineo ^a   Komatsu, Eiji ^a   Abe, Katsuyo ^a   Iyama, Shigeharu ^a   Sato, Takaaki ^a   Nagai, Masaaki ^a  

^a KITASATO INSTITUTE   (Japan)

Author keywords

Aerosol challenge model; Bordetella pertussis; Kendrick test; Pertussis vaccines

Indexed keywords

ACELLULAR VACCINE; HEMAGGLUTININ; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION;

ADHESINS, BACTERIAL; AEROSOLS; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEMAGGLUTININS; LUNG; MICE; PERTUSSIS TOXIN; PERTUSSIS VACCINE; TIME FACTORS; VACCINES, ACELLULAR; VIRULENCE FACTORS, BORDETELLA;

EID: 0037203921     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00460-1     Document Type: Article

References (30)

1. Pertussis today
2. Pertussis vaccine
3. Efficacy of whole-cell pertussis vaccine
4. Result with a new DTP vaccine in Japan
5. Development of a pertussis component vaccine in Japan
6. Type-specific efficacy of acellular pertussis vaccine
7. Efficacy and immunogenicity of acellular pertussis vaccine by manufacturer and patient age
8. Current epidemiology of pertussis in Japan
9. Pertussis vaccines in Japan
10. Overview of currently available Japanese acellular pertussis vaccines and future problems
11. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by six Japanese manufactures
12. Clinical studies on efficacy and safety of acellular pertussis vaccine
13. Mouse protection tests in the study of pertussis vaccine: A comparative series using the intracerebral route of challenge
14. Informal consulting with manufacturers and WHO Ad Hoc working group on mouse protection models for acellular pertussis vaccines
15. Evolution of control testing of pertussis vaccine
16. An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines
17. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis
18. Comparative biological activity of acellular pertussis vaccines produced by the Kitasato Institute
19. A simple chemically defined medium for the production of phase I Bordetella pertussis
20. Efficacy of chemical cross-linked antigens for acellular pertussis vaccine
21. Interaction of the Bordetella pertussisfilamentous hemagglutinin with heparin
22. Single-step purification of pertussis toxin and its subunits by heat-treated fetuin-Sepharose affinity chromatography
23. Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase
24. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
25. Efficacy of pertussis vaccines consisted of antigens detoxified with tea-leaf catechines
26. Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice
27. Bordetella pertussis infection in mice: Correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system
28. Synergistic effect of Bordetella pertussis lymphocytosis-promoting factor on protective activities of isolated Bordetella antigens in mice
29. The pyrogenicity of pertussis vaccine in mice and the factors in the vaccine responsible for this effect
30. Report of the task force on pertussis and pertussis immunization